Information Provided By:
Fly News Breaks for October 31, 2017
CBM
Oct 31, 2017 | 09:13 EDT
Craig-Hallum analyst Matt Hewitt lowered his price target for Cambrex (CBM) to $60 from $70 following last week's Q3 report by partner Gilead Sciences (GILD). Via the report, Gilead disclosed that total HCV product sales declined about 34% which coincided with about 26% less year over year patient initiations worldwide. The analyst reiterates a Buy rating on Cambrex's shares.
News For CBM From the Last 2 Days
There are no results for your query CBM